What precisely did Morgan Stanley change in the BMY analyst rating on Feb 06, 2026?

Morgan Stanley maintained an **Underweight** BMY analyst rating on **February 06, 2026** and raised its price target to **$40** from **$37**. The firm kept its cautious recommendation while increasing its fair-value estimate.

How should I interpret the maintained Underweight for Bristol-Myers Squibb Company?

A maintained Underweight means Morgan Stanley expects BMY to underperform peers near term. It suggests careful position sizing and that investors review valuation versus the updated **$40** target before trading or rebalancing.

Did the Morgan Stanley note move BMY stock and by how much?

Yes. The note corresponded with a **0.9%** move, equal to **$0.55** in the reported window. Market-cap context is **$126,145,436,318**, so price moves reflect headline sensitivity more than instant changes in fundamentals.

What does Meyka AI recommend after this BMY analyst rating update?

Meyka AI provides data and a proprietary grade; we rate BMY **B+**. Use the **BMY analyst rating**, the **$40** target, and your own risk profile to decide. These data points are informative, not investment advice.

Analyst Ratings

Morgan Stanley Maintains Underweight on BMY Bristol-Myers Squibb Company Feb 2026

ByHuzaifa Zahoor February 9, 2026February 9, 2026

On February 06, 2026 Morgan Stanley maintained an Underweight BMY analyst rating for Bristol-Myers Squibb Company and raised its price target to $40. This action keeps Morgan Stanley’s stance cautious while nudging fair value higher. The move follows Bristol-Myers Squibb’s recent Q4 2025 report and reflects updated product and pipeline assumptions. Investors should note the direct link between analyst stance and near-term stock reaction.